Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
usistapide
- Development stage
- Phase 2
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Usistapide (also known as JNJ-16269110 and R256918) is a small molecule inhibitor of microsomal triglyceride transfer protein (MTTP). It was developed by Johnson & Johnson for the treatment of obesity and type 2 diabetes. Usistapide acts by inhibiting MTTP, an essential protein involved in the assembly and secretion of very low-density lipoproteins (VLDL) in the liver and chylomicrons in the intestine, thereby reducing lipid absorption and promoting weight loss. Clinical trials evaluated its safety and efficacy primarily in overweight or obese patients, with endpoints including changes in body weight, BMI, lipid levels, glucose metabolism parameters, and other metabolic markers. The drug was administered orally as capsules. Development has been discontinued[2][7][9].
- Other names
- R256918R-256918R 256918JNJ-16269110JNJ16269110JNJ 16269110
02
Targets
MTTP (Microsomal triglyceride transfer protein large subunit)
Beyond the preview
Go deeper on usistapide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on usistapide.